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This paper outlines the history behind open access
principles and describes the development of a
managed access data-sharing process for the UK10K
Project, currently Britain’s largest genomic sequencing
consortium (2010 to 2013). Funded by the Wellcome
Trust, the purpose of UK10K was two-fold: to
investigate how low-frequency and rare genetic
variants contribute to human disease, and to provide
an enduring data resource for future research into
human genetics. In this paper, we discuss the
challenge of reconciling data-sharing principles with
the practicalities of delivering a sequencing project
of UK10K’s scope and magnitude. We describe the
development of a sustainable, easy-to-use managed
access system that allowed rapid access to UK10K
data, while protecting the interests of participants and
data generators alike. Specifically, we focus in depth
on the three key issues that emerge in the data
pipeline: study recruitment, data release and data
access.line - study recruitment, data release and data access.Introduction
The principle of open access to sequence data was estab-
lished in the Human Genome Project (1999 to 2004),
whose sequence data were published on the internet as
soon as it was available. One of the leading laboratories
in this project was the Wellcome Trust Sanger Institute
(WTSI), which, with the support of the Wellcome Trust,
continues to advocate strongly for data sharing and im-
plements data-sharing policies for most of its sequencing
projects [1]. At the time of writing, UK10K (2010 to
2013) was Britain’s largest genomic sequencing consor-
tium, having been awarded £10.5 million by the Well-
come Trust. The purpose of the award was to investigate* Correspondence: dm11@sanger.ac.uk
1The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,
Hinxton, Cambridge CB10 1SA, UK
Full list of author information is available at the end of the article
© 2013 BioMed Central Ltd.how low-frequency and rare genetic variants contribute
to human disease, and to provide the lasting legacy of a
research resource that could be used by the wider re-
search community [2].
It was decided at the outset of the project that UK10K
data should not be deposited openly on the internet and
should only be accessed through a managed access sys-
tem. This was due to the potentially sensitive nature of
some of the sample sets used, the restrictions on data
usage imposed by some Research Ethics Committees
(RECs) and the nature of the existing consents concern-
ing study participation. The challenge was to develop a
managed access system that allowed rapid access to the
data, while protecting the interests of participants and
data generators. This required putting into place a gov-
ernance system involving a series of checks and balances
that were proportionate, easy to use and sustainable in
the long term. This paper outlines the history behind
open-access principles and then goes on to describe
UK10K’s managed data access process. To illustrate
some of the challenges of implementing data-sharing
principles, we focus on three key issues in the data pipe-
During the project, we considered ethical issues such as
whether or not to provide feedback in the form of
health-related findings to research participants. Al-
though the discussion of these particular issues remains
outside the scope of this paper, the project’s procedure
for dealing with the feedback of such findings may be
found in the UK10K Ethical Governance Framework [2]
and in a separate publication by the authors [3].Open-access principles
The first international document to lay out the princi-
ples for open access in the field of genomics was the
Bermuda Agreement made in 1996 [4], followed by the
Fort Lauderdale Agreement made in 2003 [5] and
the Toronto agreement made in 2009 [6]. These docu-
ments set out the key principles that now dominate
thinking and practice regarding open access to genome
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pre-publication sequence data ‘should be freely available
and in the public domain in order to encourage research
and development and to maximize its benefit to society’
[4]. The Fort Lauderdale Agreement set out a plan for
the establishment of ‘community resources’ to achieve
rapid and open data release, as ‘community resource
datasets benefit the users enormously, giving them the
opportunity to analyze the data without the need to gen-
erate it first. The datasets are, in general, much larger,
richer and of higher quality than individual laboratories
could normally generate’ [5]. Such datasets have been
presented as the ‘drivers of progress in biomedical re-
search’ and therefore they should be ‘made immediately
available for free and unrestricted use by the scientific
community to engage in the full range of opportunities
for creative science’ [5]. In line with these principles, the
Wellcome Trust requires the researchers that it funds to
ensure that ‘genome-sequence data should be made
freely available as rapidly as possible’ [7]. Data sharing
ensures the maximum use of data that have been gener-
ated using a limited number of samples.
The principles of data sharing have been widely ac-
cepted and endorsed by the research community, but
the way that they have been implemented over the past
few years has been subject to change. A number of se-
quencing projects, such as the National Centre for Bio-
technology Information (NCBI) database of single
nucleotide polymorphisms (SNPs), the HapMap Project,
the 1000 Genomes Project and Encyclopedia of DNA El-
ements (ENCODE), have been based on the principles of
open access, which requires that sequence data are de-
posited online. When these projects were established, it
was assumed that there would be no risk of re-
identification of research participants who had donated
their DNA for sequencing. This assumption was over-
turned when the article by Homer et al. [8] demon-
strated that data from individuals could be distinguished
in genome-wide association study (GWAS) data using
only summary statistics. More recently, it was demon-
strated that male participants could be re-identified by
linking SNPs on the Y chromosome with data found in
publicly available datasets on the internet [9]. This has
resulted in a significant policy change, with some exist-
ing datasets being removed from the internet. Newer
datasets are being put into managed access systems
whenever it is considered that managing access helps to
protect research participant confidentiality; ensures that
data are used within the boundaries of consent and/or
other relevant approvals; and enables checks to be made
to ensure that data requestors are ‘bona fide’ researchers.
All of this activity has led commentators to suggest
that because of the potential identifiability of genomic
information, it is important that participants who areinvolved in genomic research understand that although
their privacy cannot be guaranteed, appropriate legal
mechanisms have been put in place to protect partici-
pants from exploitation [10].
UK10K
The UK10K project was a collaborative project that
brought together researchers working on obesity, autism,
schizophrenia, familial hypercholesterolemia, thyroid
disorders, learning disabilities, ciliopathies, congenital
heart disease, coloboma, neuromuscular disorders, and
rare disorders including severe insulin resistance. These
conditions are regarded as sensitive because of the social
stigma that may be attached to them, the health implica-
tions for individuals and their families, and the fact that
some were rare conditions only affecting small numbers
of the population. DNA samples from close to 5,500 in-
dividuals who presented with one of these disease phe-
notypes were provided by collaborators from their
existing collections. These ‘disease’ samples were whole-
exome sequenced. A further 4,000 highly phenotyped
‘control’ samples were supplied from the TwinsUK [11]
(King’s College London) registry and the ALSPAC Study
(Avon Longitudinal Study of Parents and Children, Bris-
tol University) [12]. The samples from these two studies,
referred to as the ‘cohorts’ group, were whole-genome
sequenced at 6x depth - sufficient coverage to detect
variants down to a 0.1% allele frequency. This detailed
sequence reference database was further enriched with
extensive phenotype data collected by the TwinsUK and
ALSPAC studies.
Similarly comprehensive data were generated for par-
ticipants recruited to the ‘disease’ arm of the project,
with 5,500 samples being whole-exome sequenced to
72x depth. The data generated were sufficient to dis-
cover novel rare and low-frequency variants associated
with the diseases investigated in UK10K. Further infor-
mation about the project and a list of scientific publica-
tions arising from it can be found at the UK10K Project
website [2].
To enable the project to develop insights into these
conditions and to provide an invaluable, easily used re-
source from which the whole research community might
benefit, a data pipeline had to be developed. There were
three key stages in this pipeline: recruitment of studies
or clinical collections into the project; release of the se-
quence data; and access to the dataset. The pipeline and
the various steps that were part of the governance
framework are illustrated in Figure 1 and are described
further below.
Recruitment
Setting up a project such as UK10K involved the collab-
oration of the clinicians and cohort studies that supplied
Does the study have a current 
UK Research Ethics Committee (REC) 
approval in place, and are participant consents
compatible with the project’s terms of
data management and access? 
Identification of studies to be recruited to UK10K
UK10K itself is not covered by a single 
over-arching REC approval.
Instead each sample set recruited to the
project must be able to demonstrate







The sample custodian 
retains the linkage
key and submits linked
anonymised DNA 
samples to the project 




Data released to an internal secure FTP site: to  
enable refinement of the data and project analyses 





to change their 
EGA passwords
The clock is 










is sent to PM
for review
Is the DAA satisfactorily completed?
P




















Access to UK10K datasets is made 
available to DAC-approved Data Users,
under terms of managed 
access described in the DAA 
YES NO
VCF and BAM files submitted
to the EGA on a rolling basis 
Obtain REC approval
Figure 1 Flow diagram to illustrate the process of data flow, access requests and approvals. BAM, binary alignment map; PM, project
manager; VCF, variant call file.
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resources, expertise and project management. Before the
project could commence, appropriate research partici-
pant consent and/or REC approvals had to be in place,
as did policies and processes to ensure that the storage
and use of the samples complied with relevant regula-
tions. In addition, an Ethical Governance Framework
document [2] had to be agreed upon that detailed the
data management framework. A suitable operational
governance structure for the project was also developed
to allow decision making and to ensure accountability tothe WTSI and the Wellcome Trust. Without these struc-
tures in place, there could have been significant delays
to the project or sequencing output could have been
jeopardized. The development and implementation of
UK10K’s data management framework involved identify-
ing likely challenges. In the initial stages, these included
reaching agreement on the terms of data access and the
recruitment of suitable (ethically compatible) sample
sets, the release of data using an appropriately secure
and managed mechanism, and the establishment of a
system for sustainable data sharing once the project had
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volved a number of challenges that had to be resolved.
Recruiting participant studies
Agreement had to be reached at the outset regarding the
content of the participant information sheets and con-
sent forms, so that the use of samples in the project and
the terms of data sharing were explicit. For example,
there is often an assumption that if there is mention in
the information sheets of research results being ‘pub-
lished’, that this may infer that data can be stored indef-
initely in an electronic archive and shared with other
researchers, even without specific mention that the data
will be stored in this way. Some studies had to be re-
consented before they could be included in UK10K, and
this provided an opportunity to design new information
sheets that described precisely how the data generated
by UK10K would be kept and shared with only bona fide
researchers, thus removing any ambiguity or assump-
tions. It was also important to explain that although
measures would be put in place to prevent the re-
identification of research participants from the data,
there would still be a small potential risk that this could
happen.
Use of pre-collected samples within existing consents
Patients enrolled in the studies that were included in
UK10K had consented to their materials being used in
the study for which they were originally recruited.
Nevertheless, there were differences between studies as
to how ‘broad’ the existing consents were regarding the
subsequent use of the samples in other projects. Some
consents, for example, were study-specific and the sam-
ples could not be used in other projects without first
gaining participant re-consent (as was the case for the
ALSPAC samples used in UK10K). Other studies re-
quired that results could be shared but only via a man-
aged data-access process. To address this, WTSI (as lead
institution) sought signed assurance from sample custo-
dians that the following common components of con-
sent and/or REC approval were in place prior to
accepting samples: i) appropriate consent and/or REC
approval had been sought to allow samples to be used in
UK10K; and ii) the linked anonymized data generated
could be archived indefinitely and shared with re-
searchers outside the project via the European Genome-
phenome Archive (EGA) at the European Molecular
Biology Laboratories (EMBL) Bioinformatics Institute,
Hinxton, UK.
If sample custodians were unsure as to whether the
consent provisions or REC approval covered the use of
the samples or the sharing of data, they were required to
amend their REC approval to do so. All collaborators in
the project were keen to ensure that their REC approvalswere updated, understanding and agreeing with the im-
portance of this procedure and the need to make sure
that the participants’ trust was not jeopardized.
The need to review existing consents and REC ap-
provals with potential collaborators and sample custo-
dians as early as possible in the project rapidly became
apparent, as this could have become a significant
‘rate-limiting’ step. The fixed-length project run time
meant it was necessary to exclude some studies from
UK10K as there was simply not enough time to re-
consent participants, or to request that a local REC
approve the use of sample sets collected outside of
the UK. In both instances, time was lost in establish-
ing the REC approval status of these samples, and
then in having to source alternative available studies
whose ethical approvals were compatible with inclu-
sion in UK10K.
Dovetailing with existing systems
Different sets of samples had been collected by collabo-
rators as part of distinct projects prior to any plan that
they may be used in UK10K. The recruitment of re-
search participants into the original studies had there-
fore taken place with no or little consideration that data
arising from the use of these samples may be shared
with other researchers unconnected with the immediate
project into which research participants were being re-
cruited. Ensuring that anonymized samples could be le-
gitimately used in UK10K without compromising the
original consent was a challenge for the RECs, who were
approached to review and approve amendments to the
original research proposals in order that sample sets
could be included in UK10K. Nevertheless, every REC
approached concluded that although many of the con-
sents did not specifically state that the results of the re-
search would be shared with other researchers, the
potential ‘harm’ to the research participant did not out-
weigh the benefits of the research.
For the well-established and widely used TwinsUK and
ALSPAC resources, approval and consent mechanisms
were already in place.
ALSPAC permits the sharing of data generated from
the analysis of ALSPAC samples via managed access, but
only after approval has been sought by the ALSPAC Ex-
ecutive Committee (which is responsible for coordinat-
ing all requests for new and existing data collection).
The 2,000 ALSPAC samples included in UK10K had to
be re-consented so that the participants agreed to man-
aged access of the data via the EGA. It was agreed that
the ALSPAC Executive Committee would not require
separate reports regarding requests to access ALSPAC
data in UK10K (as would usually be the case), provided
that they had a representative sitting on the UK10K
Management Committee (MC) who would see all
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ALSPAC Executive Committee as required.
By contrast, TwinsUK operates a REC-approved opt-
out system; research participants are informed about
forthcoming research studies in which their samples
may be used, including the data access processes linked
to these prospective studies. Research participants in the
TwinsUK registry automatically agree to be included in
new studies, unless they specifically opt out.
Another example of reconciling existing mechanisms
for managed data access with that of the project is
provided by the inclusion of the Generation Scotland
sample set. Generation Scotland is a multi-institution,
population-based resource [13], and a condition of
agreeing to UK10K’s management of access to the data
derived from their samples was that any requests to use
these data would be reported back to a Generation
Scotland sample resource representative, thus satisfying
their own metrics for monitoring data usage.
Although TwinsUK, ALSPAC and Generation Scotland
operated different approval systems, it was clear to us
that a good, informed relationship between research par-
ticipants and these projects was key. In addition, sample
custodians and associated steering committees under-
stood the benefit of sharing data with other researchers,
despite their own investment in setting-up the initial
projects and recruiting research participants.
Data release
Once the necessary approvals had been confirmed, sam-
ples were submitted to WTSI for genome or exome se-
quencing. It was decided at the outset that the EGA
would house both all sequence data generated by
UK10K and phenotype data for selected traits, such as
height and body mass index (BMI), that were collected
by both the TwinsUK and ALSPAC studies. Data were
released to the EGA as a series of cumulative ‘rolling re-
leases’ - so that as newer, more complete datasets for
each sample set were generated, they were made avail-
able to approved data users as soon as possible. It was
initially hoped to release data on a quarterly basis, but
making releases at such specific intervals ultimately
proved impossible because of the increasing length of
time required to prepare progressively larger and more
complex datasets for EGA submission. Instead, datasets
were released as soon as it was possible to do so. So
as not to hinder project progress, the collaborators
(sample custodians) who had provided samples and were
collaborating on primary analyses with WTSI-based re-
searchers were able to access the data internally via a se-
cure FTP site rather than waiting to access data through
the EGA.
Each time a new data release was made, the EGA
would send an automated email alert to all approveddata users with existing access rights, informing them of
the need to update their password. Initially this caused
some confusion in the data management process, as it
was not clear to data users why they were being
prompted to change their login details. This was quickly
resolved when the EGA amended the alert to explain
that UK10K studies had been updated with additional
dataset(s) and that a new password was required in
order to maintain security, prompting data users to ac-
cess the latest version of the data.
To protect study participants, a great deal of effort
was invested in protecting the privacy of the data. Some
of the disease phenotypes included in UK10K were so
rare or at such extreme ends of a disease spectrum, and
the number of documented cases were so few, that these
patients could potentially have been at risk of re-
identification. It was agreed at the start of the project
that sequence data would only be made available to
third-party researchers outside the project in a linked
anonymized (coded or pseudonymized) form, and that
samples would be provided to UK10K by collaborators
(sample custodians) in a linked anonymized form with
the linkage key retained by the sample custodian. This
ensured that the collaborating principal investigator
(sample custodian) would be the only party able to link
data back to the research participants’ identity. This in-
cluded, but was not exclusive to, situations in which the
collaborator also held a clinical duty of care to the re-
search participants. In this way, patient identity was pro-
tected both within and outside of the project when the
data were released to the EGA. This system also enabled
clinically significant findings to be returned to partici-
pants, after a number of checks had been carried out ac-
cording to the UK10K policy [2].
Data access
The commitment to data-sharing principles in research
requires a considerable amount of time and resources to
manage requests for access. There were two bodies that
were responsible for oversight of UK10K data-access re-
quests from researchers outside of the project (a model
based on the Wellcome Trust Case–control Consortium
(WTCCC) Data Access process); the MC and the Well-
come Trust Data Access Committee (DAC). Composed
of representatives from each of the cohort and disease
groups, the MC acted as the first formal stage of review
for applications to use project data. To ensure the most
efficient use of MC time, applications were first checked
by the UK10K project manager (PM). This informal re-
view at the point of submission ensured that all requests
brought before the MC were valid, correctly executed
and respected the constraints of dataset usage. The
DAC was set up by the Wellcome Trust to be independ-
ent from the project and, once approved by the MC,
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formal approval. The DAC were then responsible for
requesting that the EGA create the appropriate user ac-
counts for the data requestors.
As already mentioned briefly, researchers wishing to
use UK10K data could contact the UK10K PM as the
designated, visible point of contact with any queries re-
garding data usage, before submitting their request in
the form of a completed UK10K data-access application
(designed specifically for the project). The preliminary
(informal) review of all data access applications included
a number of considerations, which are summarized in
Box 1.
Having confirmed that an application was satisfactorily
completed (and if necessary contacting the applicant to
resolve any issues), the PM would then inform the MC
of the application. Provided that no queries or issues
were raised by the MC, the PM would then send the re-
quest onto the DAC who, acting independently of the
project, would consider the request in more detail and
approved it, request that the PM contact the applicant
to address any concerns raised or rejected it. Once ap-
proved, the DAC would contact successful applicants to
confirm this outcome and instruct the EGA to create an
account with appropriate access permissions for all ap-
proved data users. It was proposed that there should be
a maximum two-month turnaround time from receipt
of a data-access application to the issuing of EGA login
details, though, in practice, the procedure sometimes
took longer than this, in part because the DAC met
less frequently to review applications than was initially
anticipated.
The publication moratorium
A publication moratorium was put in place to protect
the first publication rights of the project’s researchers,
sample custodians and data producers. The terms of the
moratorium were explained as part of the UK10K Publi-
cation Policy (Appendix B of the data access applica-
tion), and state that ‘All data will no longer be subject toBox 1. The UK10K project manager’s review
• Was the document completed satisfactorily?
• Were contact details provided for all listed prospective data users?
• Was the application co-signed by an authorized representative of the
• Were the recent publications listed by the lead applicant authentic?
• Was there an adequate description of the proposed research?
• Were the datasets listed in the application appropriate for that resear
• Would use of those datasets in that way conflict with or violate any c
controls where the data access agreement specified that to do so wa
dataset.)the publication moratorium once the data have been
published, or until one year has passed since the full
dataset required for analysis was released’. Once data
began being submitted to the EGA, it quickly became
apparent to the MC that a more precise definition was
required for what constituted a dataset that was ‘full’
enough to enable meaningful analyses. It was agreed that
the moratorium ‘clock’ would start from when the ma-
jority of samples (≥90%) had sequence data available
in the EGA. For the cohort studies (TwinsUK and
ALSPAC), the publication moratorium on the whole-
genome datasets expired on 2 July 2013, and for
all other exome studies, the moratorium expires on 2
January 2014. To ensure complete clarity regarding the
expiration of the publication moratorium, these dates
were included in the project’s data access application
document, were posted on the project website and were
also added to the dataset descriptions in the EGA.
The first consequence of violating the moratorium, or
indeed breaching any term of the UK10K data-access
agreement, is that the DAC and/or the MC would in-
struct the EGA to terminate data access immediately.
Once a breach had been confirmed, the DAC and/or
MC would contact the appropriate journal requesting
that any manuscripts using UK10K data be withdrawn.
The project took its obligation to protect the publication
rights of the researchers, sample custodians and data
producers very seriously. As part of the managed-access
process, the DAC was asked to stress the requirement
for strict adherence to the publication moratorium, par-
ticularly to those data users approved for access during
the early stages of data availability. Periodic checks of
the literature were made by the PM to ensure that
UK10K data had not been published prematurely (pre-
moratorium expiry), or used for purposes other than
those on which the basis for data access was granted.
Succession planning
As a project with a fixed duration of 42 months, it was
essential that UK10K also developed a plan for thedata user’s institute?
ch?
onstraints on their terms of use? (For instance, using datasets as
s not permissible according to the consents attached to that
Table 1 Setting up a managed access data resource: project checklist
Pre-project
✓ Have all pre-collected sample collections been identified for inclusion in the project?
✓ For these studies, do the sample custodians agree in principle to the potential inclusion of their sample sets in the project?
✓ For those studies willing to participate in the project, have the sample custodians confirmed total sample numbers available within the required
timeframe for the project?
✓ Have they also confirmed the REC approval status for these samples?
Specifically has the sample custodian provided signed assurance that:
• appropriate consent and/or REC approvals are in place for the use of samples in the project, and are compatible with the terms of data
sharing proposed by the project;
• where appropriate consents and/or REC approvals are not in place, there is sufficient time to correct this within the timeframe of the
project (if not, these studies should be excluded at the outset);
• a mechanism is in place for sample custodians to withdraw the use of their samples;
• the potential risks of participant identification (however minimal) have been explained;
• all of these points have been documented in, for example, an Ethical Governance Framework, and is this document available to data users
both inside and outside the consortium.
Data collection stage
✓ Has it been made clear to the sample custodian that DNA samples must be submitted in a linked (coded) anonymized form, with the sample
custodian retaining the linkage key?
✓ Do the sample custodians agree with the timeframe for submitting their samples, and the amount and quality of material required for
sequencing?
Preparing for managing data access
✓ Has a comprehensive, project management committee-approved data-access document been prepared that includes:
• a description of all available datasets and any constraints on the use of the data;
• the project’s publication policy;
• a clear explanation of the publication moratoria (if applicable) and its expiry dates;
• a named point-of-contact to whom completed applications (and any queries) should be submitted; in the UK10K example this was the
project manager (PM).
✓ Has the data access document been made available for download at the site of released data (that is, the resource; in this case the EGA), and/or
on the project website?
✓ Has a person or group independent from the project been identified and appointed to function as a Data Access Committee (DAC)? Have they
been briefed on the terms of data access?
✓ Is there a mechanism in place to arrange for approved data users to access the datasets in the resource once the DAC has approved the data
request? If not, this needs to be put in place.
Data release stage
✓ Have the data been deposited into the Resource in a linked anonymized (pseudonymized) form, so that third-party data users are unable to
identify study participants?
✓ Is the project tracking applications that are made to use project data? (For UK10K, applications were monitored by the PM from the point of
receiving an application through to the DAC notifying the PM that the application had been formally approved.)
✓ Providing information as to how datasets are being used may be a condition of some studies’ permitting the inclusion of their samples in the
project; and failure to do so may result in the dataset being withdrawn.
✓ Are approved data users notified as and when additional datasets are added to the resource?
Post-project
✓ If the project is of a fixed duration, has a mechanism been put into place for managing data access once the project’s management structure
dissolves?
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data once the MC dissolved at the end of the project. To
this end, it was agreed that in the absence of a PM and
MC, all data access applications would be submitted in-
stead to the WTSI’s newly designated Data Access Offi-
cer. This officer would review proposals, seek DACapproval, and liaise with the EGA to create and maintain
data-user accounts. To ensure a smooth transition, this
handover process was initiated several months before
the close of the project. Additionally, contact details for
the sample providers (sample custodians) were added to
each of the UK10K studies in the EGA and were also
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website, so that data users could direct queries to an ap-
propriate contact after the MC had disbanded.
Conclusion
As advances in technology further reduce the cost of
genomic sequencing, the more accessible and widely
used this technology will become, generating ever larger
and more complex datasets. The UK10K managed-
access system is one example of how it is possible to re-
lease data widely while still respecting the contributions
of all those involved in the project and the regulatory
requirements. While funders advocate data sharing,
there are no hard rules governing how groups should
manage and share the data generated. Endeavors such as
UK10K are, by their very nature, unique - driven by the
particular participating institutes and their local policies,
influenced by the varying demands of funders, and re-
quired to adhere to the specific ethical constraints of
consent and/or REC approval attached to the use of par-
ticipant materials (be that biological material and/or
data). As such, the UK10K model is not intended to be
taken as an example of recommended practice, but ra-
ther a collection of lessons learned that could prove
useful to others undertaking a similar approach to data
sharing. Table 1 is a checklist that captures the crucial
questions that, from experience, are useful to raise
and address when establishing a managed data-access
system.
A great deal of anticipation, planning and time were
required to set up and then successfully deliver a gen-
omic sequencing project of UK10K’s scope and magni-
tude. Having a designated PM role was crucial to
coordinating the implementation of data-management
processes as well as to the day-to-day running of the
project. A wider group of people (other than researchers
and sample providers) were involved in the project than
might have been expected; these included administrative
staff, regulatory and policy advisers, database and IT
support, patient representatives, an independent DAC,
an Ethics Advisory Group, the MC and also a project
publications committee.
Finally, it should be noted that UK10K has successfully
achieved its two core goals: rare and low-frequency vari-
ants associated with disease have been detected (primary
papers describing these results are currently in prepar-
ation; with secondary consortium papers already pub-
lished to the project website [2]); and a managed access
data resource has been produced that will benefit the
genetics research community around the world. At the
time of writing, over 75 applications have been received
and approved, allowing successful applicants to down-
load UK10K data via the EGA from researchers spread
across the global research community: in Taiwan,Canada, China, USA, Australia and Europe (specifically
the UK, Finland, the Netherlands, France, Switzerland
and Austria). Once the project’s primary results are pub-
lished and UK10K is increasingly cited in the literature,
we anticipate a rapid increase in the demand for use of
the data as awareness of the data resource spreads.
Maximum use of the samples donated has been ensured
by sharing the data with researchers outside of the consor-
tium. Furthermore, in making the data available on a
rolling basis as they are generated, rather than at the pro-
ject’s end, this benefit has been realized immediately.
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